# Dolutegravir/Rilpivirine, Antiretroviral Efficacy Study Using Real-world Data in Subjects With Human Immunodeficiency Virus (HIV)-1

> **NCT03518060** · — · COMPLETED · sponsor: **ViiV Healthcare** · enrollment: 209 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** JULUCA

## Key facts

- **NCT ID:** NCT03518060
- **Lead sponsor:** ViiV Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-25
- **Primary completion:** 2023-05-14
- **Final completion:** 2023-05-14
- **Target enrollment:** 209 (ACTUAL)
- **Last updated:** 2024-10-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03518060

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03518060, "Dolutegravir/Rilpivirine, Antiretroviral Efficacy Study Using Real-world Data in Subjects With Human Immunodeficiency Virus (HIV)-1". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03518060. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*